Good morning :)
Place Order
Add to Watchlist

Thyrocare Technologies Ltd

THYROCARE

Thyrocare Technologies Ltd

THYROCARE
Health CareHospitals & Diagnostic Centres
SmallcapWith a market cap of ₹5,407 cr, stock is ranked 769
Moderate RiskStock is 2.61x as volatile as Nifty
1,009.500.63% (-6.40)
1,009.500.63% (-6.40)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CareHospitals & Diagnostic Centres
SmallcapWith a market cap of ₹5,407 cr, stock is ranked 769
Moderate RiskStock is 2.61x as volatile as Nifty

How to use scorecard? Learn more

Health CareHospitals & Diagnostic Centres
SmallcapWith a market cap of ₹5,407 cr, stock is ranked 769
Moderate RiskStock is 2.61x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
64.3910.25—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.906.610.52%

Forecast & Ratings

Detailed Forecast 
100%
Analysts have suggested that investors can buy this stock

from 2 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Thyrocare Technologies Limited is a diagnostic chain company which offers a range of medical diagnostic tests and profiles of tests that center on early detection and management of disorders and diseases.

Investor Presentation

View older 

Oct 23, 2024

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 7.06%, vs industry avg of 10.02%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 1.13% to 0.94%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of -3.63%, vs industry avg of 42.9%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue247.51316.63379.32413.52441.44507.05618.11536.27581.64635.83
Raw Materialssubtract69.6881.7894.61110.79117.17163.86170.57163.03166.98467.79
Power & Fuel Costsubtract5.326.356.687.778.697.648.4010.7010.15
Employee Costsubtract25.7032.0035.3443.3548.9258.0761.13106.15107.86
Selling & Administrative Expensessubtract28.8946.1449.5759.2744.4842.1645.4752.6973.23
Operating & Other expensessubtract17.3350.1727.5927.5048.0151.7067.7471.5774.90
Depreciation/Amortizationsubtract18.2418.0520.1026.1731.9130.2833.8738.7147.0150.96
Interest & Other Itemssubtract0.550.460.440.611.850.873.214.835.533.94
Taxes & Other Itemssubtract30.0038.8351.7152.9252.0139.3251.5824.1025.2229.17
EPS9.947.9817.3615.9916.7421.4133.3012.1913.3715.86
DPS10.0010.0010.0020.005.0025.0015.0018.000.0018.00
Payout ratio1.011.250.581.250.301.170.451.480.001.14

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

Apr 30PDF
Feb 12PDF
Feb 12PDF
+2 more
FY 2023

Annual report

PDF

Investor Presentation

Feb 3PDF
Nov 11PDF
Aug 1PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 1PDF
FY 2025

Annual Report Pending

Investor Presentation

Oct 23PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CareHospitals & Diagnostic Centres

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Thyrocare Technologies Ltd76.4210.25—
Apollo Hospitals Enterprise Ltd115.7214.210.22%
Max Healthcare Institute Ltd97.8212.300.14%
Fortis Healthcare Ltd89.626.270.14%

Price Comparison

Compare THYROCARE with any stock or ETF
Compare THYROCARE with any stock or ETF
THYROCARE
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

High Pledged Promoter Holding

Lower pledged promoter holdings is considered better

A significant proportion of promoter holdings is pledged

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding71.11%12.90%1.90%1.93%12.16%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep3.44%3.46%3.35%2.90%2.49%1.93%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Thyrocare Technologies Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Nippon India Small Cap Fund - Growth - Direct Plan

Growth
3.6459%0.32%0.04%84/234 (+60)
Nippon India Pharma Fund - Growth - Direct Plan

Growth
3.2669%2.04%0.29%19/38 (+5)
Quant Small Cap Fund - Growth - Direct Plan

Growth
1.9243%0.38%0.06%27/98 (+5)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateAug 16, 2024

Final
Final | Div/Share: ₹18.00

Dividend/Share

₹18.00

Ex DateEx Date

Aug 16, 2024

Cash Dividend

Ex DateEx DateApr 20, 2023

Interim
Interim | Div/Share: ₹18.00

Dividend/Share

₹18.00

Ex DateEx Date

Apr 20, 2023

Cash Dividend

Ex DateEx DateMay 11, 2022

Interim
Interim | Div/Share: ₹15.00

Dividend/Share

₹15.00

Ex DateEx Date

May 11, 2022

Cash Dividend

Ex DateEx DateJun 17, 2021

Final
Final | Div/Share: ₹15.00

Dividend/Share

₹15.00

Ex DateEx Date

Jun 17, 2021

Cash Dividend

Ex DateEx DateNov 12, 2020

Interim
Interim | Div/Share: ₹10.00

Dividend/Share

₹10.00

Ex DateEx Date

Nov 12, 2020

News & Opinions
Spotlight
Thyrocare Tech hits 52 week high as Q2 PAT jumps 31% YoY to Rs 27 cr

Revenue from operations grew by 19.99% year on year (YoY) to Rs 177.36 crore in the quarter ended 30 September 2024. Profit before tax in Q2 FY25 stood at Rs 36.78 crore, up 30.10% as against Rs 28.27 crore posted in same quarter last year. Total expenses rose 16.88% YoY to Rs 142.90 crore during the quarter. Cost of materials and services consumed was at Rs 50.12 crore (up 16.34% YoY) while employee benefits expense stood at Rs 29.49 crore (up 8.98%) during the period under review. The company's revenue from Diagnostic Testing Services was at Rs 161.92 crore (up 18.40% YoY) while revenue from Imaging Services stood at Rs 14.15 crore (up 20.83% YoY) in Q1 FY25. EBITDA improved 28% YoY to Rs 48.2 crore in September 2024 quarter from Rs 37.6 crore reported in corresponding period previous year. EBITDA margin increased to 27% in Q2 FY25 as compared to 25% reported in the corresponding quarter last fiscal. On half year basis, the company's net profit jumped 35.06% to Rs 50.84 crore on 18.16% rise in revenue to Rs 334.27 crore in H1 FY25 over H1 FY24. Thyrocare Technologies is engaged in the healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India. The counter has hit a 52-week high at Rs 957.95 in today's intra-day session.Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Thyrocare Technologies consolidated net profit rises 31.12% in the September 2024 quarter

Net profit of Thyrocare Technologies rose 31.12% to Rs 26.67 crore in the quarter ended September 2024 as against Rs 20.34 crore during the previous quarter ended September 2023. Sales rose 19.84% to Rs 177.36 crore in the quarter ended September 2024 as against Rs 148.00 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales177.36148.00 20 OPM %27.0625.35 - PBDT49.8538.92 28 PBT36.7828.27 30 NP26.6720.34 31 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Thyrocare Technologies schedules board meeting

Thyrocare Technologies will hold a meeting of the Board of Directors of the Company on 23 October 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Thyrocare Technologies announces cessation of director

Thyrocare Technologies announced the cessation of Neetin Shivajirao Desai (DIN No: 02622364) as Independent Director of the company with effect from 19 September 2024 on completion of second term. Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Thyrocare Tech to acquire diagnostic and pathological services of Vimta Lab

Thyrocare Technologies said that it shall have access to 11 centres of Vimta Labs at the locations such as Telangana, Andhra Pradesh, Uttar Pradesh and Odisha. The central processing laboratory, which is also a National Accreditation Board for Testing and Calibration Laboratories (NABL) accredited laboratory, is situated in Hyderabad, it added. Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs 30 crore during FY 2024 and Rs 7 Crore in Q1 FY 2025. The company added that the completion of the acquisition is subject to fulfilment of the conditions precedent. Rahul Guha, MD & CEO, Thyrocare Technologies, said, 'This strategic move aligns with our growth objectives, allowing Thyrocare to expand its market share, solidify our leadership position in South India, and grow our business with franchisees and hospitals. Additionally, this expansion will enable Thyrocare to leverage the benefits of scale.' Thyrocare Technologies is engaged in the healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India. Vimta Labs is a leading contract research and testing services provider in India. Shares of Thyrocare Technologies shed 0.10% to Rs 864.05 while those of Vimta Labs slipped 2.24% to Rs 627.55 on the BSE. Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Thyrocare to acquire diagnostic and pathological services of Vimta Lab

Thyrocare Technologies has signed a Business Transfer Agreement for purchase of the diagnostic and pathological services business of Vimta Labs. Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs 30 crore during FY 2024 and Rs 7 crore in Q1 FY 2025.Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Thyrocare Technologies AGM scheduled

Thyrocare Technologies announced that the Annual General Meeting (AGM) of the company will be held on 23 August 2024.Powered by Capital Market - Live

4 months agoCapital Market - Live

Thyrocare expands Northern India presence with Polo Labs acquisition

4 months agoBusiness Standard

Thyrocare Q1 Results Review - Margin Thesis Is Starting To Unfold: ICICI Securities

4 months agoBloomberg Quint

Gainers & Losers: Dabur, Avanti Feeds among 9 stocks in limelight on Wednesday

4 months agoEconomic Times